ResMed Inc. (RMD) — financial distillation
Annual history (10-K)
Quarterly history (10-Q)
Two headline lines are shown to start. Click any item in a legend to add or remove it — every figure on the chart is one the table below also carries, for the period it names.
In brief, from the full filed history
- Revenue grew from $920.7M (period ending 2009-06-30) to $5.65B (period ending 2026-06-30) — a 11.3% annual pace across 17 year(s) of filed history.
- Net margin expanded from 15.9% to 26.9% over that same span.
- Across 51 tracked quarters, the strongest was $1.43B (quarter ending 2026-03-31) and the weakest was $247.0M (quarter ending 2009-09-30).
Annual — most recent 10-K
| Line | Value | Period ends | Form | Filing |
|---|---|---|---|---|
| Revenue | $5.65B | 2026-06-30 | 10-K | 0000943819-26-000047 |
| Gross profit | $3.45B | 2026-06-30 | 10-K | 0000943819-26-000047 |
| Operating income | $1.89B | 2026-06-30 | 10-K | 0000943819-26-000047 |
| Net income | $1.52B | 2026-06-30 | 10-K | 0000943819-26-000047 |
| Diluted EPS | $10.43 | 2026-06-30 | 10-K | 0000943819-26-000047 |
| Total assets | $8.97B | 2026-06-30 | 10-K | 0000943819-26-000047 |
| Total liabilities | $2.38B | 2026-06-30 | 10-K | 0000943819-26-000047 |
| Cash & equivalents | $1.47B | 2026-06-30 | 10-K | 0000943819-26-000047 |
| Operating cash flow | $1.81B | 2026-06-30 | 10-K | 0000943819-26-000047 |
Quarterly — most recent 10-Q
| Line | Value | Period ends | Form | Filing |
|---|---|---|---|---|
| Revenue | $1.43B | 2026-03-31 | 10-Q | 0000943819-26-000025 |
| Gross profit | $891.0M | 2026-03-31 | 10-Q | 0000943819-26-000025 |
| Operating income | $499.8M | 2026-03-31 | 10-Q | 0000943819-26-000025 |
| Net income | $398.7M | 2026-03-31 | 10-Q | 0000943819-26-000025 |
| Diluted EPS | $2.74 | 2026-03-31 | 10-Q | 0000943819-26-000025 |
| Total assets | $8.78B | 2026-03-31 | 10-Q | 0000943819-26-000025 |
| Total liabilities | $2.29B | 2026-03-31 | 10-Q | 0000943819-26-000025 |
| Cash & equivalents | $1.66B | 2026-03-31 | 10-Q | 0000943819-26-000025 |
| Operating cash flow | $457.3M | 2025-09-30 | 10-Q | 0000943819-25-000090 |
Reading
The figures above are taken directly from filings with the U.S. Securities and Exchange Commission. The reading below was generated by a local language model from only those figures; it introduces no numbers of its own. It is not investment advice.
ResMed Inc. (RMD) operates with a substantial scale, as evidenced by its $5.65 billion annual revenue and $8.97 billion total assets as of the period ending 2026-06-30. The company’s mix is predominantly focused on healthcare, specifically in the sleep apnea and other respiratory disorders treatment sector. Over the past 17 years, ResMed has demonstrated a robust revenue growth trajectory, averaging an 11.3% annual pace, as per the pre-computed trend facts. This growth is further underscored by the expansion of net margin from 15.9% to 26.9% over the same period.
The multi-year revenue trend indicates a consistent upward trajectory, with each successive year surpassing its predecessor. Notably, the company’s revenue has quadrupled from $920.7 million in 2009 to $5.65 billion in 2026. This growth pattern suggests a strong market position and effective execution of business strategies. The quarterly figures also reflect this trend, with the most recent quarter ending 2026-03-31 reporting revenue of $1.43 billion, the highest in the company’s history.
In the upcoming filings, investors should monitor ResMed’s ability to sustain this growth rate and maintain its expanding margins. Additionally, the company’s cash and equivalents, standing at $1.47 billion as of 2026-06-30, will be a key metric to track, given its role in funding future growth initiatives and managing liabilities. The operating cash flow, which stood at $1.81 billion for the period ending 2026-06-30, also provides insight into the company’s operational efficiency and cash generation capabilities.
Source: SEC EDGAR company facts for CIK 0000943819 · filings index